Gefitinib for Epidermal Growth Factor Receptor Activated Osteoarthritis Subpopulation Treatment

Area of Science:

• Biomedical research
• Orthopedics
• Molecular biology

Background:

• Osteoarthritis (OA) is a major cause of disability in aging populations.
• Current treatments cannot restore cartilage homeostasis (synthesis vs. degradation).
• OA lacks precise subpopulation classification, impeding personalized medicine.

Purpose of the Study:

• Identify OA subpopulations.
• Investigate the role of epidermal growth factor receptor (EGFR) in OA pathogenesis.
• Evaluate EGFR inhibition as a therapeutic strategy for OA.

Main Methods:

• Identified an OA subpopulation with high EGFR activation.
• Utilized Col2a1-creER^T2; Egfr^f/f mice to study EGFR function in vivo.
• Assessed the effect of EGFR inhibition using the FDA-approved drug gefitinib.

Main Results:

• EGFR activation, indicated by phosphorylation (pEGFR), correlated with joint destruction in mice.
• EGFR inhibition prevented cartilage degeneration and promoted regeneration.
• Gefitinib restored cartilage structure and function in a mouse model and a clinical case.

Conclusions:

• Established the concept of an EGFR-activated OA subpopulation.
• Demonstrated EGFR signaling's role in regulating cartilage homeostasis.
• Gefitinib is a potential disease-modifying drug for this specific OA subpopulation.